Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6912)
All Articles published online
|
Jun 28, 2010 (publication date) through Nov 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 2010; 16(24): 2963-2970 [PMID: 20572298 DOI: 10.3748/wjg.v16.i24.2963] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v16/i24/2963.htm |
| Number | Citing Articles |
| 1 |
Alessandro Zerbi, Vanessa Capitanio, Letizia Boninsegna, Gianfranco Delle Fave, Claudio Pasquali, Guido Rindi, Davide Campana, Massimo Falconi. Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study. HPB 2013; 15(12): 935 doi: 10.1111/hpb.12065
|
| 2 |
Jonathan R. Strosberg. Systemic Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS): Cuirrent Approaches and Future Options. Endocrine Practice 2014; 20(2): 167 doi: 10.4158/EP13262.RA
|
| 3 |
Jun Fan, Lili Deng, Ying Peng, Yuedi Ding. Combined anti-tumor efficacy of somatostatin fusion protein and vaccinia virus on tumor cells with high expression of somatostatin receptors. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-21506-8
|
| 4 |
Aldona Kasprzak, Agnieszka Geltz. The State-of-the-Art Mechanisms and Antitumor Effects of Somatostatin in Colorectal Cancer: A Review. Biomedicines 2024; 12(3): 578 doi: 10.3390/biomedicines12030578
|
| 5 |
Akshat Saxena, Terence C. Chua, Marlon Perera, Francis Chu, David L. Morris. Surgical resection of hepatic metastases from neuroendocrine neoplasms: A systematic review. Surgical Oncology 2012; 21(3): e131 doi: 10.1016/j.suronc.2012.05.001
|
| 6 |
Daniel Putzer, Alexander Kroiss, Dietmar Waitz, Michael Gabriel, Tatjana Traub-Weidinger, Christian Uprimny, Elisabeth von Guggenberg, Clemens Decristoforo, Boris Warwitz, Gerlig Widmann, Irene Johanna Virgolini. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide. European Journal of Nuclear Medicine and Molecular Imaging 2013; 40(3): 364 doi: 10.1007/s00259-012-2286-6
|
| 7 |
Mauro Cives, Jonathan Strosberg. The Expanding Role of Somatostatin Analogs in Gastroenteropancreatic and Lung Neuroendocrine Tumors. Drugs 2015; 75(8): 847 doi: 10.1007/s40265-015-0397-7
|
| 8 |
Isabella Reccia, Madhava Pai, Jayant Kumar, Duncan Spalding, Andrea Frilling. Tumour Heterogeneity and the Consequent Practical Challenges in the Management of Gastroenteropancreatic Neuroendocrine Neoplasms. Cancers 2023; 15(6): 1861 doi: 10.3390/cancers15061861
|
| 9 |
Ágota Petrányi, György Bodoky. Drugs for the treatment of neuroendocrine tumours. Orvosi Hetilap 2011; 152(10): 379 doi: 10.1556/OH.2011.29060
|
| 10 |
Agnieszka Milewska-Kranc, Jarosław B. Ćwikła, Agnieszka Kolasinska-Ćwikła. The Role of Receptor–Ligand Interaction in Somatostatin Signaling Pathways: Implications for Neuroendocrine Tumors. Cancers 2023; 16(1): 116 doi: 10.3390/cancers16010116
|
| 11 |
Chanjuan Shi, David S. Klimstra. Pancreatic neuroendocrine tumors: Pathologic and molecular characteristics. Seminars in Diagnostic Pathology 2014; 31(6): 498 doi: 10.1053/j.semdp.2014.08.008
|
| 12 |
Kjell E Öberg. Management of neuroendocrine tumors: current and future therapies. Expert Review of Endocrinology & Metabolism 2011; 6(1): 49 doi: 10.1586/eem.10.81
|
| 13 |
Alejandro Garcia-Alvarez, Jorge Hernando Cubero, Jaume Capdevila. Drug Development in Neuroendocrine Tumors: What Is on the Horizon?. Current Treatment Options in Oncology 2021; 22(5) doi: 10.1007/s11864-021-00834-3
|
| 14 |
Marc Remke, Esther Hering, Nicolas U. Gerber, Marcel Kool, Dominik Sturm, Christian H. Rickert, Joachim Gerß, Stefan Schulz, Thomas Hielscher, Martin Hasselblatt, Astrid Jeibmann, Volkmar Hans, Vijay Ramaswamy, Michael D. Taylor, Torsten Pietsch, Stefan Rutkowski, Andrey Korshunov, Carmelia-Maria Monoranu, Michael C. Frühwald. Somatostatin receptor subtype 2 (sst2) is a potential prognostic marker and a therapeutic target in medulloblastoma. Child's Nervous System 2013; 29(8): 1253 doi: 10.1007/s00381-013-2142-4
|
| 15 |
Sirine Jaber, Veronica Nemska, Ivan Iliev, Elena Ivanova, Tsvetelina Foteva, Nelly Georgieva, Ivan Givechev, Dimiter Tanev, Emilia Naydenova, Dancho Danalev.
Synthesis, antiproliferative and antimicrobial activities of (KLAKLAK)
2
-NH
2
analogue containing nor-Leu and its conjugates with a second pharmacophore
. Biotechnology & Biotechnological Equipment 2023; 37(1): 151 doi: 10.1080/13102818.2022.2162965
|
| 16 |
Annemiek Walenkamp, Guillermo Crespo, Felipe Fierro Maya, Reidar Fossmark, Peter Igaz, Anja Rinke, Gianluca Tamagno, Giovanni Vitale, Kjell Öberg, Tim Meyer. Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment. Endocrine-Related Cancer 2014; 21(6): R445 doi: 10.1530/ERC-14-0106
|
| 17 |
Laura Lattanzio, Federica Tonissi, Martino Monteverde, Gerard Milano, Marco C. Merlano, Cristiana Lo Nigro. Differential molecular mechanism of docetaxel–octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells. Anti-Cancer Drugs 2013; 24(2): 120 doi: 10.1097/CAD.0b013e328358d1dc
|
| 18 |
Elizabeta Popa, Felice Schnoll‐Sussman, Arun Jesudian, Govind Nandakumar, Manish A. Shah. Textbook of Uncommon Cancer. 2012; : 389 doi: 10.1002/9781118464557.ch28
|
| 19 |
C.J. Auernhammer, C. Spitzweg, V. Heinemann, B. Göke. Medikamentöse Therapie bei metastasierten neuroendokrinen Tumoren des gastroenteropankreatischen Systems. Wiener klinisches Magazin 2013; 16(3): 16 doi: 10.1007/s00740-013-0114-7
|
| 20 |
Alan Meeker, Christopher Heaphy. Gastroenteropancreatic endocrine tumors. Molecular and Cellular Endocrinology 2014; 386(1-2): 101 doi: 10.1016/j.mce.2013.07.015
|
| 21 |
L. E. Gurevich, N. A. Korsakova, I. A. Voronkova, V. E. Ashevskaya , A. G. Titov, L. M. Kogoniya, A. V. Egorov, T. A. Britvin, I. A. Vasil'ev. IMMUNOHISTOCHEMICAL DETERMINATION OF EXPRESSION OF SOMATOSTATIN RECEPTORS TYPES 1, 2A, 3 AND 5 IN NEUROENDOCRINE TUMORS OF VARIOUS LOCALIZATION AND GRADE. Almanac of Clinical Medicine 2016; 44(4): 378 doi: 10.18786/2072-0505-2016-44-4-378-390
|
| 22 |
Aayushi Sood, Malak Munir, Omar Syed, Vidhi Mehta, Ravleen Kaur, Arathi Kumar, Archana Sridhar, Akshit Sood, Rahul Gupta. An update on the safety of lanreotide autogel for the treatment of patients with neuroendocrine tumors. Expert Opinion on Drug Safety 2024; 23(8): 949 doi: 10.1080/14740338.2024.2365823
|
| 23 |
Daphne Adelman, Xuan-Mai Truong Thanh, Marion Feuilly, Aude Houchard, David Cella. Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO). Advances in Therapy 2020; 37(4): 1608 doi: 10.1007/s12325-020-01255-8
|
| 24 |
Ryo Shimoyama, Susumu Hijioka, Nobumasa Mizuno, Gakuto Ogawa, Tomoko Kataoka, Hiroshi Katayama, Nozomu Machida, Yoshitaka Honma, Narikazu Boku, Tetsuya Hamaguchi, Haruhiko Fukuda, Masanori Terashima, Yukihide Kanemitsu, Junji Furuse. Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors; Japan Clinical Oncology Group Study JCOG1901 (STARTER-NET study). Pancreatology 2020; 20(6): 1183 doi: 10.1016/j.pan.2020.07.010
|
| 25 |
Maridi Aerts, Hendrik Reynaert. Disease Control on Lanreotide Autogel® 120 mg in a Patient with Metastatic Gastrinoma: A Case Report. Case Reports in Gastroenterology 2017; 11(3): 616 doi: 10.1159/000485025
|
| 26 |
Dan Granberg. Advances in Pulmonary Neuroendocrine Tumor Management. 2013; : 36 doi: 10.2217/ebo.12.79
|
| 27 |
Aura D. Herrera-Martínez, Antonio C. Fuentes-Fayos, Rafael Sanchez-Sanchez, Antonio J. Montero, André Sarmento-Cabral, María A. Gálvez-Moreno, Manuel D. Gahete, Raúl M. Luque. Does Telotristat Have a Role in Preventing Carcinoid Heart Disease?. International Journal of Molecular Sciences 2024; 25(4): 2036 doi: 10.3390/ijms25042036
|
| 28 |
Tetsuhide Ito, Yoshitaka Honma, Susumu Hijioka, Atsushi Kudo, Akira Fukutomi, Akira Nozaki, Yasutoshi Kimura, Fuyuhiko Motoi, Hiroyuki Isayama, Izumi Komoto, Seiichi Hisamatsu, Akihiro Nakajima, Akira Shimatsu. Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors. Investigational New Drugs 2017; 35(4): 499 doi: 10.1007/s10637-017-0466-8
|
| 29 |
Philipp Melhorn, Elisabeth Kretschmer-Chott, Ladislaia Wolff, Alexander Haug, Peter Mazal, Markus Raderer, Barbara Kiesewetter. Treatment patterns and oncological outcome of patients with advanced small intestinal neuroendocrine tumors: real-world data from the Medical University of Vienna. Therapeutic Advances in Medical Oncology 2022; 14 doi: 10.1177/17588359221138389
|
| 30 |
Jonathan Strosberg. Neuroendocrine tumours of the small intestine. Best Practice & Research Clinical Gastroenterology 2012; 26(6): 755 doi: 10.1016/j.bpg.2012.12.002
|
| 31 |
Tadashi Sakane, Tomoharu Nakano, Emi Hagui, Hiroshi Haneda, Katsuhiro Okuda. Everolimus in combination with octreotide LAR in thymic atypical carcinoid. Thoracic Cancer 2023; 14(15): 1404 doi: 10.1111/1759-7714.14887
|
| 32 |
C.J. Auernhammer, C. Spitzweg, V. Heinemann, B. Göke. Medikamentöse Therapie bei metastasierten neuroendokrinen Tumoren des gastroenteropankreatischen Systems. Der Internist 2012; 53(2): 167 doi: 10.1007/s00108-011-2919-z
|
| 33 |
Thomas Walter, Hedia Brixi-Benmansour, Catherine Lombard-Bohas, Guillaume Cadiot. New treatment strategies in advanced neuroendocrine tumours. Digestive and Liver Disease 2012; 44(2): 95 doi: 10.1016/j.dld.2011.08.022
|
| 34 |
A. Amador Cano, F. García, A. Espinoza, N. Bezies, E. Herrera, J. De Leija Portilla. Nonfunctional neuroendocrine tumor of the pancreas: Case report and review of the literature. International Journal of Surgery Case Reports 2013; 4(2): 225 doi: 10.1016/j.ijscr.2012.10.018
|
| 35 |
Josefina C. Farra, Steven E. Rodgers. Surgical Endocrinopathies. 2015; : 323 doi: 10.1007/978-3-319-13662-2_53
|
| 36 |
Tak Geun Oh, Moon Jae Chung, Jeong Yeop Park, Seung Min Bang, Seung Woo Park, Jae Bok Chung, Si Young Song. Prognostic Factors and Characteristics of Pancreatic Neuroendocrine Tumors: Single Center Experience. Yonsei Medical Journal 2012; 53(5): 944 doi: 10.3349/ymj.2012.53.5.944
|
| 37 |
Hisato Igarashi, Masayuki Hijioka, Lingaku Lee, Tetsuhide Ito. Biotherapy of pancreatic neuroendocrine tumors using somatostatin analogs. Journal of Hepato-Biliary-Pancreatic Sciences 2015; 22(8): 618 doi: 10.1002/jhbp.227
|
| 38 |
Willem Lybaert, Erik Van Hul, Heidi Woestenborghs. Long-Term Disease Control of a Pancreatic Neuroendocrine Tumor with Lanreotide Autogel®: A Case Report. Case Reports in Oncology 2014; 7(3): 673 doi: 10.1159/000368207
|
| 39 |
Sirine Jaber, Ivan Iliev, Tsvetelina Angelova, Veronica Nemska, Inna Sulikovska, Emilia Naydenova, Nelly Georgieva, Ivan Givechev, Ivo Grabchev, Dancho Danalev. Synthesis, Antitumor and Antibacterial Studies of New Shortened Analogues of (KLAKLAK)2-NH2 and Their Conjugates Containing Unnatural Amino Acids. Molecules 2021; 26(4): 898 doi: 10.3390/molecules26040898
|
| 40 |
Jonathan Strosberg. The American Cancer Society's Oncology in Practice. 2018; : 552 doi: 10.1002/9781118592168.ch39
|
| 41 |
|
| 42 |
Kathleen K. Christians, George Younan, Ben George, Susan Tsai, Douglas B. Evans. Difficult Decisions in Endocrine Surgery. Difficult Decisions in Surgery: An Evidence-Based Approach 2018; : 441 doi: 10.1007/978-3-319-92860-9_36
|
| 43 |
Maxime Palazzo, Catherine Lombard-Bohas, Guillaume Cadiot, Tamara Matysiak-Budnik, Vinciane Rebours, Marie-Pierre Vullierme, Anne Couvelard, Olivia Hentic, Philippe Ruszniewski. Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors. European Journal of Gastroenterology & Hepatology 2013; 25(2): 232 doi: 10.1097/MEG.0b013e328359d1a6
|
| 44 |
Christos Toumpanakis, Martyn E. Caplin. Update on the Role of Somatostatin Analogs for the Treatment of Patients With Gastroenteropancreatic Neuroendocrine Tumors. Seminars in Oncology 2013; 40(1): 56 doi: 10.1053/j.seminoncol.2012.11.006
|
| 45 |
Sirine Jaber, Veronica Nemska, Ivan Iliev, Elena Ivanova, Tsvetelina Foteva, Nelly Georgieva, Ivan Givechev, Emilia Naydenova, Veronika Karadjova, Dancho Danalev. Synthesis and Biological Studies on (KLAKLAK)2-NH2 Analog Containing Unnatural Amino Acid β-Ala and Conjugates with Second Pharmacophore. Molecules 2021; 26(23): 7321 doi: 10.3390/molecules26237321
|
| 46 |
Emilia Naydenova, Diana Wesselinova, Svetlana Staykova, Dancho Danalev, Tatyana Dzimbova. Synthesis, in vitro biological activity and docking of new analogs of BIM-23052 containing unnatural amino acids. Amino Acids 2019; 51(9): 1247 doi: 10.1007/s00726-019-02758-7
|
| 47 |
Svetlana Ts. Staykova, Diana W. Wesselinova, Lyubomir T. Vezenkov, Emilia D. Naydenova. Synthesis and in vitro antitumor activity of new octapeptide analogs of somatostatin containing unnatural amino acids. Amino Acids 2015; 47(5): 1007 doi: 10.1007/s00726-015-1929-x
|
| 48 |
Elisabeth Fabian, Bernhard Haas, Patrizia Kump, Rainer Lipp, Peter Kornprat, Andre Lutfi, Emina Talakic, Michael Fuchsjäger, Walter Spindelboeck, Carolin Lackner, Gernot Zollner, Guenter J. Krejs. Clinical–Pathological Conference Series from the Medical University of Graz. Wiener klinische Wochenschrift 2016; 128(7-8): 277 doi: 10.1007/s00508-016-0965-1
|
| 49 |
M. Albertelli, E. Nazzari, S. Sciallero, F. Grillo, S. Morbelli, F. De Cian, G. Cittadini, E. Ambrosetti, A. Ciarmiello, D. Ferone. Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study. Journal of Endocrinological Investigation 2017; 40(11): 1265 doi: 10.1007/s40618-017-0692-0
|
| 50 |
Aleksandra Marciniak, Justyna Brasuń. Somatostatin analogues labeled with copper radioisotopes: current status. Journal of Radioanalytical and Nuclear Chemistry 2017; 313(2): 279 doi: 10.1007/s10967-017-5323-x
|
| 51 |
Lucas Sidéris, Pierre Dubé, Anja Rinke. Antitumor Effects of Somatostatin Analogs in Neuroendocrine Tumors. The Oncologist 2012; 17(6): 747 doi: 10.1634/theoncologist.2011-0458
|
| 52 |
Anna J Sharp, Aimee R Hayes, Ashley Grossman. High-dose Somatostatin Analogues for Progressive Neuroendocrine Tumours. European Endocrinology 2020; 16(2): 93 doi: 10.17925/EE.2020.16.2.93
|
| 53 |
Dermot O’Toole, Pamela L. Kunz, Susan M. Webb, Grace Goldstein, Sheila Khawaja, Mark McDonnell, Sandra Boiziau, Delphine Gueguen, Aude Houchard, Antonio Ribeiro-Oliveira, Ally Prebtani. PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly. Advances in Therapy 2023; 40(2): 671 doi: 10.1007/s12325-022-02360-6
|
| 54 |
Tetsuhide Ito, Hisato Igarashi, Hirotsugu Uehara, Robert T Jensen. Pharmacotherapy of Zollinger–Ellison syndrome. Expert Opinion on Pharmacotherapy 2013; 14(3): 307 doi: 10.1517/14656566.2013.767332
|
| 55 |
Sara Lopes, Marta Alves, Pedro Rodrigues. Vasoactive Intestinal Peptide Tumor as the Cause of Persistent Diarrhea: A Diagnostic Challenge. Cureus 2022; doi: 10.7759/cureus.29130
|
| 56 |
Rui-Lin Xie, Rui Liang, Yuan-Yuan Luo, Zhuo-Hao Ruan, Yi-Fu Li, Wen-Sheng Liu. Growth Axis Somatostatin, Growth Hormone Receptor, and Insulin-like Growth Factor-1 Genes Express and Are Affected by the Injection of Exogenous Growth Hormone in Chinemys reevesii. Genes 2023; 14(11): 2032 doi: 10.3390/genes14112032
|
| 57 |
E. Wynendaele, E. Pauwels, C. Van de Wiele, C. Burvenich, B. De Spiegeleer. The potential role of quorum-sensing peptides in oncology. Medical Hypotheses 2012; 78(6): 814 doi: 10.1016/j.mehy.2012.03.018
|
| 58 |
A. Viúdez, A. De Jesus-Acosta, F.L. Carvalho, R. Vera, S. Martín-Algarra, N. Ramírez. Pancreatic neuroendocrine tumors: Challenges in an underestimated disease. Critical Reviews in Oncology/Hematology 2016; 101: 193 doi: 10.1016/j.critrevonc.2016.03.013
|
| 59 |
Dancho Danalev, Ivan Iliev, Stefan Dobrev, Silvia Angelova, Stoiko Petrin, Tatyana Dzimbova, Elena Ivanova, Dessislava Borisova, Emilia Naydenova. Synthesis, Antiproliferative Effect and In Silico LogP Prediction of BIM-23052 Analogs Containing Tyr Instead of Phe. Pharmaceutics 2023; 15(4): 1123 doi: 10.3390/pharmaceutics15041123
|
| 60 |
Gary B. Deutsch, Ji Hey Lee, Anton J. Bilchik. Long-Term Survival with Long-Acting Somatostatin Analogues Plus Aggressive Cytoreductive Surgery in Patients with Metastatic Neuroendocrine Carcinoma. Journal of the American College of Surgeons 2015; 221(1): 26 doi: 10.1016/j.jamcollsurg.2015.03.055
|
| 61 |
Rosa Maria Paragliola, Roberto Salvatori. Novel Somatostatin Receptor Ligands Therapies for Acromegaly. Frontiers in Endocrinology 2018; 9 doi: 10.3389/fendo.2018.00078
|
| 62 |
Frédérique Maire, Philippe Ruszniewski. Somatostatin Analogues. 2015; : 189 doi: 10.1002/9781119031659.ch17
|
| 63 |
Jonathan R. Strosberg, Asima Cheema, Larry K. Kvols. A Review of Systemic and Liver-Directed Therapies for Metastatic Neuroendocrine Tumors of the Gastroenteropancreatic Tract. Cancer Control 2011; 18(2): 127 doi: 10.1177/107327481101800207
|
| 64 |
Kyung Won Kim, Katherine M. Krajewski, Mizuki Nishino, Jyothi P. Jagannathan, Atul B. Shinagare, Sree Harsha Tirumani, Nikhil H. Ramaiya. Update on the Management of Gastroenteropancreatic Neuroendocrine Tumors With Emphasis on the Role of Imaging. American Journal of Roentgenology 2013; 201(4): 811 doi: 10.2214/AJR.12.10240
|
| 65 |
Tetsuhide Ito, Hisato Igarashi, Robert T. Jensen. Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. Journal of Gastroenterology 2012; 47(9): 941 doi: 10.1007/s00535-012-0642-8
|
| 66 |
Su-Chen Li, Cécile Martijn, Tao Cui, Ahmed Essaghir, Raúl M. Luque, Jean-Baptiste Demoulin, Justo P. Castaño, Kjell Öberg, Valeria Giandomenico, Miguel López. The Somatostatin Analogue Octreotide Inhibits Growth of Small Intestine Neuroendocrine Tumour Cells. PLoS ONE 2012; 7(10): e48411 doi: 10.1371/journal.pone.0048411
|
| 67 |
Heloisa Prado Soares, Jonathan Strosberg. Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances. 2016; : 505 doi: 10.1007/978-1-4939-3426-3_28
|
| 68 |
Jean Claude Reubi, Agnes Schonbrunn. Illuminating somatostatin analog action at neuroendocrine tumor receptors. Trends in Pharmacological Sciences 2013; 34(12): 676 doi: 10.1016/j.tips.2013.10.001
|
| 69 |
Jonathan Strosberg. Evolving Treatment Strategies for Management of Carcinoid Tumors. Current Treatment Options in Oncology 2013; 14(3): 374 doi: 10.1007/s11864-013-0246-4
|
| 70 |
Theresa R. Harring, N. Thao N. Nguyen, John A. Goss, Christine A. O'Mahony. Treatment of Liver Metastases in Patients with Neuroendocrine Tumors: A Comprehensive Review. International Journal of Hepatology 2011; 2011: 1 doi: 10.4061/2011/154541
|
| 71 |
Esther Una Cidon. New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future. World Journal of Gastrointestinal Oncology 2017; 9(1): 4-20 doi: 10.4251/wjgo.v9.i1.4
|
| 72 |
Ysabel C. Ilagan-Ying, Emily Y. Park, Robert Lam, Shaili Gupta. Pancreatic Neuroendocrine Tumor Presenting with Chylous Ascites: Multidisciplinary Workup to Differentiate from Malignant Ascites. Journal of General Internal Medicine 2022; 37(8): 2082 doi: 10.1007/s11606-022-07463-y
|
| 73 |
Aura D. Herrera-Martínez, Manuel D. Gahete, Sergio Pedraza-Arevalo, Rafael Sánchez-Sánchez, Rosa Ortega-Salas, Raquel Serrano-Blanch, Raúl M. Luque, María A. Gálvez-Moreno, Justo P. Castaño. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. Endocrine 2018; 59(2): 426 doi: 10.1007/s12020-017-1482-3
|
| 74 |
B. Kiesewetter, P. Mazal, E. Kretschmer-Chott, M.E. Mayerhoefer, M. Raderer. Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice. ESMO Open 2022; 7(3): 100478 doi: 10.1016/j.esmoop.2022.100478
|
| 75 |
A. Nießen, S. Schimmack, F. Billmann, T. Hackert. Chirurgie bei neuroendokrinen Neoplasien des Pankreas: State of the Art. Die Chirurgie 2022; 93(8): 745 doi: 10.1007/s00104-022-01641-8
|
| 76 |
Giuseppe Nigri, Niccolò Petrucciani, Tarek Debs, Livia Maria Mangogna, Anna Crovetto, Giovanni Moschetta, Raffaello Persechino, Paolo Aurello, Giovanni Ramacciato. Treatment options for PNET liver metastases: a systematic review. World Journal of Surgical Oncology 2018; 16(1) doi: 10.1186/s12957-018-1446-y
|
| 77 |
Tetsuhide Ito, Hisato Igarashi, Robert T. Jensen. Zollinger–Ellison syndrome. Current Opinion in Gastroenterology 2013; 29(6): 650 doi: 10.1097/MOG.0b013e328365efb1
|
| 78 |
Daniela Molè, Erica Gentilin, Alejandro Ibañez-Costa, Teresa Gagliano, Manuel D. Gahete, Federico Tagliati, Roberta Rossi, Maria Rosa Pelizzo, Giancarlo Pansini, Raúl M. Luque, Justo P. Castaño, Ettore degli Uberti, Maria Chiara Zatelli. The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells. Endocrine 2015; 50(2): 442 doi: 10.1007/s12020-015-0594-x
|
| 79 |
Catherine T. Anthony, Juan G. Bastidas, Jessica L. Thomson, John Lyons, James M. Lewis, Joshua E. Schwimer, Peter Casey, Jennifer Abadie, Daniel J. Frey, Yi-Zarn Wang, J. Philip Boudreaux, Eugene A. Woltering. A Study of Pipeline Drugs in Neuroendocrine Tumors. Journal of Gastrointestinal Cancer 2012; 43(2): 296 doi: 10.1007/s12029-011-9286-9
|
| 80 |
Aleksandra Marciniak, Marek Cebrat, Żaneta Czyżnikowska, Justyna Brasuń. Novel short-chain analogues of somatostatin as ligands for Cu(II) ions. Role of the metal ion binding on the spatial structure of the ligand. Journal of Inorganic Biochemistry 2012; 117: 10 doi: 10.1016/j.jinorgbio.2012.08.023
|
| 81 |
Taymeyah Al-Toubah, Jonathan Strosberg. Neuroendocrine Tumours. 2024; : 619 doi: 10.1007/978-3-031-56968-5_30
|
| 82 |
Robert T. Jensen. Yamada' s Textbook of Gastroenterology. 2015; : 1078 doi: 10.1002/9781118512074.ch57
|
| 83 |
Tetsuhide Ito, Nao Fujimori, Yoshitaka Honma, Atsushi Kudo, Susumu Hijioka, Shinji Katsushima, Yasutoshi Kimura, Akira Fukutomi, Seiichi Hisamatsu, Akihiro Nakajima, Akira Shimatsu. Long‐term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors: Final results of a phase II open‐label extension study. Asia-Pacific Journal of Clinical Oncology 2021; 17(5) doi: 10.1111/ajco.13371
|
| 84 |
Michaela S. Banck, Andreas S. Beutler. Advances in small bowel neuroendocrine neoplasia. Current Opinion in Gastroenterology 2014; 30(2): 163 doi: 10.1097/MOG.0000000000000043
|
| 85 |
Sara Massironi, Dario Conte, Roberta Elisa Rossi. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules. Scandinavian Journal of Gastroenterology 2016; 51(5): 513 doi: 10.3109/00365521.2015.1115117
|
| 86 |
Susumu Hijioka, Chigusa Morizane, Masafumi Ikeda, Hiroshi Ishii, Takuji Okusaka, Junji Furuse. Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives. Japanese Journal of Clinical Oncology 2021; 51(8): 1185 doi: 10.1093/jjco/hyab076
|
| 87 |
Venkata K. Pokuri, Mei Ka Fong, Renuka Iyer. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors. Current Oncology Reports 2016; 18(1) doi: 10.1007/s11912-015-0492-7
|
| 88 |
Stefano Cappato, Federica Brena, Michela Squadroni, Rosalba Barile, Davide Piccinali, Annalisa Mancin, Giorgio Quartierini, Orlando Goletti, Giordano Beretta. Clinical Applications of Nuclear Medicine Targeted Therapy. 2018; : 153 doi: 10.1007/978-3-319-63067-0_14
|
| 89 |
MUHITTIN ERTILAV, ENDER HUR, DEVRIM BOZKURT, SAVAS SIPAHI, OZGE TIMUR, BANU SARSIK, FEHMI AKCICEK, SONER DUMAN. Octreotide lessens peritoneal injury in experimental encapsulated peritoneal sclerosis model. Nephrology 2011; 16(6): 552 doi: 10.1111/j.1440-1797.2011.01460.x
|
| 90 |
Emilio Bajetta, Laura Catena, Nicola Fazio, Sara Pusceddu, Pamela Biondani, Giusi Blanco, Sergio Ricci, Michele Aieta, Francesca Pucci, Monica Valente, Nadia Bianco, Chiara Maria Mauri, Francesca Spada. Everolimus in combination with octreotide long‐acting repeatable in a first‐line setting for patients with neuroendocrine tumors: An ITMO group study. Cancer 2014; 120(16): 2457 doi: 10.1002/cncr.28726
|
| 91 |
Marta Martín-Richard, Bartomeu Massutí, Eva Pineda, Vicente Alonso, Maribel Marmol, Daniel Castellano, Emilio Fonseca, Antonio Galán, Marta Llanos, Maria Angeles Sala, Carlos Pericay, Fernando Rivera, Javier Sastre, Ángel Segura, Maria Quindós, Pascal Maisonobe. Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study. BMC Cancer 2013; 13(1) doi: 10.1186/1471-2407-13-427
|
| 92 |
Nitya Raj, Elizabeth Cruz, Sarah O'Shaughnessy, Claudia Calderon, Joanne F. Chou, Marinela Capanu, Olivia Heffernan, April DeMore, Sippy Punn, Tiffany Le, Haley Hauser, Leonard Saltz, Diane Reidy-Lagunes. A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors. JCO Oncology Practice 2022; 18(9): e1533 doi: 10.1200/OP.22.00055
|